News | July 05, 2023
Syngene to acquire multi-modal facility from Stelis Biopharma
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Subscribe To Our Newsletter & Stay Updated
